<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36371497</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration.</ArticleTitle><Pagination><StartPage>6901</StartPage><MedlinePgn>6901</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6901</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-022-34620-y</ELocationID><Abstract><AbstractText>Superoxide dismutase (SOD1) gene variants may cause amyotrophic lateral sclerosis, some of which are associated with a distinct phenotype. Most studies assess limited variants or sample sizes. In this international, retrospective observational study, we compare phenotypic and demographic characteristics between people with SOD1-ALS and people with ALS and no recorded SOD1 variant. We investigate which variants are associated with age at symptom onset and time from onset to death or censoring using Cox proportional-hazards regression. The SOD1-ALS dataset reports age of onset for 1122 and disease duration for 883 people; the comparator population includes 10,214 and 9010 people respectively. Eight variants are associated with younger age of onset and distinct survival trajectories; a further eight associated with younger onset only and one with distinct survival only. Here we show that onset and survival are decoupled in SOD1-ALS. Future research should characterise rarer variants and molecular mechanisms causing the observed variability.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Opie-Martin</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9NU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Iacoangeli</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5280-5017</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9NU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics and Health Informatics, Institute of Psychiatry Psychology &amp; Neuroscience, King's College London, SE5 8AF, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topp</LastName><ForeName>Simon D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0002-5200-3284</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9NU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abel</LastName><ForeName>Olubunmi</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Homerton University Hospital, Homerton Row, London, E9 6SR, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayl</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9NU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Puja R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0002-0255-407X</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9NU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shatunov</LastName><ForeName>Aleksey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9NU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Clinical Pharmacology, University of Liverpool, Blue Block 1.09, Sherrington Building, Crown St, Liverpool, L693BX, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medicine, North-Eastern Federal University, 58 Belinsky str, Yakutsk, 677000, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fogh</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9NU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowles</LastName><ForeName>Harry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9NU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Limbachiya</LastName><ForeName>Naomi</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0200-4676</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9NU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spargo</LastName><ForeName>Thomas P</ForeName><Initials>TP</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9NU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Khleifat</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7406-9831</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9NU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Kelly L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0001-6319-9473</Identifier><AffiliationInfo><Affiliation>Macquarie University Centre for MND Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jockel-Balsarotti</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bali</LastName><ForeName>Taha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Self</LastName><ForeName>Wade</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-1648-6124</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henden</LastName><ForeName>Lyndal</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-5541-7637</Identifier><AffiliationInfo><Affiliation>Macquarie University Centre for MND Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Garth A</ForeName><Initials>GA</Initials><Identifier Source="ORCID">0000-0001-9694-066X</Identifier><AffiliationInfo><Affiliation>Macquarie University Centre for MND Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Concord Clinical School, ANZAC Research Institute, Concord Repatriation Hospital, Sydney, NSW, 2139, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ticozzi</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5963-7426</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, 20095, Cusano Milanino, MiIan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dino Ferrari Center, Department of Pathophysiology and Transplantation, Center for Neurotechnology and Brain Therapeutics, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKenna-Yasek</LastName><ForeName>Diane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 02125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing, 100191, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-8925-2567</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, S10 2HQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chio</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology 1, AOU Citt&#xe0; della Salute e della Scienza of Torino, Turin, 10124, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Oberer Eselsberg 45, 89081, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases, DZNE, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weishaupt</LastName><ForeName>Jochen H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurodegenerative Disorders, Department of Neurology, Mannheim Center for Translational Neuroscience, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landers</LastName><ForeName>John E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0001-8084-5043</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 02125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-3295-4971</Identifier><AffiliationInfo><Affiliation>Department Neurology, Emory University School of Medicine, Atlanta, GA, 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora</LastName><ForeName>Jesus S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0001-6633-5354</Identifier><AffiliationInfo><Affiliation>ALS Unit, Department of Neurology, Hospital San Rafael, 28016, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robberecht</LastName><ForeName>Wim</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Neurology Department, Univeristy Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damme</LastName><ForeName>Philip Van</ForeName><Initials>PV</Initials><Identifier Source="ORCID">0000-0002-4010-2357</Identifier><AffiliationInfo><Affiliation>Neurology Department, Univeristy Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Department, KU Leuven and Center for Brain &amp; Disease Research VIB Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLaughlin</LastName><ForeName>Russell</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3915-2135</Identifier><AffiliationInfo><Affiliation>Complex Trait Genomics Laboratory, Smurfit Institute of Genetics, Trinity College Dublin, Dublin, D02 PN40, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, D02 PN40, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0001-5572-9657</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Phillippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre de R&#xe9;f&#xe9;rence pour la SLA et les Autres Maladies du Motoneurone (FILSLAN), 2 Avenue Martin Luther King, 87042, Limoges Cedex, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de Comp&#xe9;tences Neuropathies Amylo&#xef;des Familiales et Autres Neuropathies P&#xe9;riph&#xe9;riques Rares (NNERF), Poitiers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevic</LastName><ForeName>Zorica</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of Belgrade, Studentski trg 1, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddique</LastName><ForeName>Nailah</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neuromuscular Disorders Program, Northwestern University, Feinberg School of Medicine, Chicago, IL, 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, 20095, Cusano Milanino, MiIan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dino Ferrari Center, Department of Pathophysiology and Transplantation, Center for Neurotechnology and Brain Therapeutics, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blair</LastName><ForeName>Ian P</ForeName><Initials>IP</Initials><AffiliationInfo><Affiliation>Macquarie University Centre for MND Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Dong-Sheng</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing, 100191, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esselin</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Reference Center for ALS and Other Rare Motoneuron Disorders, University Hospital Gui de Chauliac, 34295, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Cruz</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3345-1628</Identifier><AffiliationInfo><Affiliation>Reference Center for ALS and Other Rare Motoneuron Disorders, University Hospital Gui de Chauliac, 34295, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camu</LastName><ForeName>William</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-1287-7355</Identifier><AffiliationInfo><Affiliation>Reference Center for ALS and Other Rare Motoneuron Disorders, University Hospital Gui de Chauliac, 34295, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basak</LastName><ForeName>Nazli A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Ko&#xe7; University, School of Medicine Translational Medicine Research Center KUTTAM-NDAL, 34450, Sar&#x131;yer, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddique</LastName><ForeName>Teepu</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7293-9146</Identifier><AffiliationInfo><Affiliation>Neuromuscular Disorders Program, Northwestern University, Feinberg School of Medicine, Chicago, IL, 60208, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, MO, 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><Identifier Source="ORCID">0000-0001-6062-1528</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 02125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9NU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute Centre at King's College London, School of Neuroscience, King's College London, Strand, London, WC2R 2LS, UK. chris.shaw@kcl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Brain Research, University of Auckland, 85 Park Road, Grafton, Auckland, 1023, New Zealand. chris.shaw@kcl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 NS073873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MCLAUGHLIN/OCT15/957-799</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>J.H.V. reports to have sponsored research agreements with Biogen. P.V.D. holds a senior clinical investigatorship of FWO-Vlaanderen and is supported by the E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders, the ALS Liga Belgi&#xeb; and the KU Leuven funds &#x201c;Een Hart voor ALS&#x201d;, &#x201c;Laeversfonds voor ALS Onderzoek&#x201d; and the &#x201c;Val&#xe9;ry Perrier Race against ALS Fund&#x201d;. Several authors of this publication (A.C., A.L., J.W., L.B., O.H., V.S.) are members of the European Reference Network for Rare Neuromuscular Diseases (ERN-NMD). The remaining authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>13</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36371497</ArticleId><ArticleId IdType="pmc">PMC9653399</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-34620-y</ArticleId><ArticleId IdType="pii">10.1038/s41467-022-34620-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rosen DR, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z-Y, et al. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J. Neurol., Neurosurg. Psychiatry. 2017;88:540. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw CE, et al. Mutations in all five exons of SOD-1 may cause ALS. Ann. Neurol. 1998;43:390&#x2013;394. doi: 10.1002/ana.410430319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410430319</ArticleId><ArticleId IdType="pubmed">9506558</ArticleId></ArticleIdList></Reference><Reference><Citation>Daoud H, et al. C9orf72 hexanucleotide repeat expansions as the causative mutation for chromosome 9p21&#x2013;linked amyotrophic lateral sclerosis and frontotemporal dementia. Arch. Neurol. 2012;69:1159&#x2013;1163. doi: 10.1001/archneurol.2012.377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.377</ArticleId><ArticleId IdType="pubmed">22964911</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H, Gao K, Jankovic J. The role of FUS gene variants in neurodegenerative diseases. Nat. Rev. Neurol. 2014;10:337&#x2013;348. doi: 10.1038/nrneurol.2014.78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.78</ArticleId><ArticleId IdType="pubmed">24840975</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Rademakers R. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. Curr. Opin. Neurol. 2008;21:693&#x2013;700. doi: 10.1097/WCO.0b013e3283168d1d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e3283168d1d</ArticleId><ArticleId IdType="pmc">PMC2869081</ArticleId><ArticleId IdType="pubmed">18989115</ArticleId></ArticleIdList></Reference><Reference><Citation>Wicks P, et al. SOD1 and cognitive dysfunction in familial amyotrophic lateral sclerosis. J. Neurol. 2009;256:234&#x2013;241. doi: 10.1007/s00415-009-0078-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-0078-0</ArticleId><ArticleId IdType="pubmed">19252762</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H-F, Wu Z-Y. Genotype-phenotype correlations of amyotrophic lateral sclerosis. Transl. Neurodegener. 2016;5:3. doi: 10.1186/s40035-016-0050-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-016-0050-8</ArticleId><ArticleId IdType="pmc">PMC4738789</ArticleId><ArticleId IdType="pubmed">26843957</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D, Hergesheimer R, Vourc&#x2019;h P, Corcia P, Blasco H. TDP43 aggregates: the &#x2018;Schr&#xf6;dinger&#x2019;s cat&#x2019; in amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2021;22:514. doi: 10.1038/s41583-021-00477-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-021-00477-1</ArticleId><ArticleId IdType="pubmed">34103710</ArticleId></ArticleIdList></Reference><Reference><Citation>Tziortzouda P, Van Den Bosch L, Hirth F. Reply to &#x2018;TDP43 aggregates: the &#x2018;Schr&#xf6;dinger&#x2019;s cat&#x2019; in amyotrophic lateral sclerosis&#x2019;. Nat. Rev. Neurosci. 2021;22:515. doi: 10.1038/s41583-021-00478-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-021-00478-0</ArticleId><ArticleId IdType="pubmed">34103711</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali T, et al. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J. Neurol. Neurosurg. Psychiatry. 2017;88:99&#x2013;105. doi: 10.1136/jnnp-2016-313521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-313521</ArticleId><ArticleId IdType="pmc">PMC5136332</ArticleId><ArticleId IdType="pubmed">27261500</ArticleId></ArticleIdList></Reference><Reference><Citation>Parton MJ, et al. D90A-SOD1 mediated amyotrophic lateral sclerosis: a single founder for all cases with evidence for a Cis-acting disease modifier in the recessive haplotype. Hum. Mutat. 2002;20:473. doi: 10.1002/humu.9081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.9081</ArticleId><ArticleId IdType="pubmed">12442272</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang L., Ma Y., Liu X.-L., Chen L. &amp; Fan D.-S. Better survival in female SOD1-mutant patients with ALS: a study of SOD1-related natural history. Transl. Neurodegener.;8:2 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6325854</ArticleId><ArticleId IdType="pubmed">30637102</ArticleId></ArticleIdList></Reference><Reference><Citation>McCann EP, et al. The genotype&#x2013;phenotype landscape of familial amyotrophic lateral sclerosis in Australia. Clin. Genet. 2017;92:259&#x2013;266. doi: 10.1111/cge.12973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cge.12973</ArticleId><ArticleId IdType="pubmed">28105640</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., et al. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 383: 109&#x2013;119 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13:1108&#x2013;1113. doi: 10.1016/S1474-4422(14)70219-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70219-4</ArticleId><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, et al. The multistep hypothesis of ALS revisited: the role of genetic mutations. Neurology. 2018;91:e635&#x2013;e42. doi: 10.1212/WNL.0000000000005996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005996</ArticleId><ArticleId IdType="pmc">PMC6105040</ArticleId><ArticleId IdType="pubmed">30045958</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel O, Powell JF, Andersen PM, Al-Chalabi A. ALSoD: a user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum. Mutat. 2012;33:1345&#x2013;1351. doi: 10.1002/humu.22157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22157</ArticleId><ArticleId IdType="pubmed">22753137</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Rheenen W, et al. Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. Eur. J. Hum. Genet. 2018;26:1537&#x2013;1546. doi: 10.1038/s41431-018-0177-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-018-0177-4</ArticleId><ArticleId IdType="pmc">PMC6138692</ArticleId><ArticleId IdType="pubmed">29955173</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatunov A, et al. Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol. 2010;9(10):986&#x2013;994. doi: 10.1016/S1474-4422(10)70197-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70197-6</ArticleId><ArticleId IdType="pmc">PMC3257853</ArticleId><ArticleId IdType="pubmed">20801717</ArticleId></ArticleIdList></Reference><Reference><Citation>Galaleldeen A, et al. Structural and biophysical properties of metal-free pathogenic SOD1 mutants A4V and G93A. Arch. Biochem. Biophys. 2009;492:40&#x2013;47. doi: 10.1016/j.abb.2009.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2009.09.020</ArticleId><ArticleId IdType="pmc">PMC2787720</ArticleId><ArticleId IdType="pubmed">19800308</ArticleId></ArticleIdList></Reference><Reference><Citation>South A. rworldmap: a new R package for mapping global. Data. R. J. 2011;3:35&#x2013;43.</Citation></Reference><Reference><Citation>Team R. C. R.: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing 2020.</Citation></Reference><Reference><Citation>Therneau T. M. A Package for Survival Analysis in R. 2021.</Citation></Reference><Reference><Citation>Wickham H. ggplot2: Elegant Graphics for Data Analysis: Springer-Verlag New York; 2016.</Citation></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor. Neuron. Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, et al. Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin. Eur. J. Epidemiol. 2016;31:229&#x2013;245. doi: 10.1007/s10654-015-0090-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-015-0090-x</ArticleId><ArticleId IdType="pubmed">26458931</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Lewis CM. Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum. Hered. 2011;71:281&#x2013;288. doi: 10.1159/000330167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000330167</ArticleId><ArticleId IdType="pubmed">21846995</ArticleId></ArticleIdList></Reference><Reference><Citation>Henden L, et al. Identity by descent analysis identifies founder events and links SOD1 familial and sporadic ALS cases. npj Genom. Med. 2020;5:32. doi: 10.1038/s41525-020-00139-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41525-020-00139-8</ArticleId><ArticleId IdType="pmc">PMC7414871</ArticleId><ArticleId IdType="pubmed">32789025</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan M., et al. Determining the incidence of familiality in ALS: a study of temporal trends in Ireland from 1994 to 2016. Neurol. Genet.4: e239-e (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961194</ArticleId><ArticleId IdType="pubmed">29845113</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 2016;48:1043&#x2013;1048. doi: 10.1038/ng.3622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3622</ArticleId><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Keum JW, et al. The HTT CAG-expansion mutation determines age at death but not disease duration in huntington disease. Am. J. Hum. Genet. 2016;98:287&#x2013;298. doi: 10.1016/j.ajhg.2015.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2015.12.018</ArticleId><ArticleId IdType="pmc">PMC4746370</ArticleId><ArticleId IdType="pubmed">26849111</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta PR, et al. Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias. J. Neurol. Neurosurg. Psychiatry. 2019;90:268&#x2013;271. doi: 10.1136/jnnp-2018-319089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319089</ArticleId><ArticleId IdType="pmc">PMC6518463</ArticleId><ArticleId IdType="pubmed">30270202</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink JH. ALS genetic epidemiology &#x2018;How simplex is the genetic epidemiology of ALS?&#x2019;. J. Neurol. Neurosurg. Psychiatry. 2017;88:537. doi: 10.1136/jnnp-2016-315469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315469</ArticleId><ArticleId IdType="pubmed">28209650</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan PK, et al. Structural similarity of wild-type and ALS-mutant superoxide dismutase-1 fibrils using limited proteolysis and atomic force microscopy. Proc. Natl Acad. Sci. 2013;110:10934. doi: 10.1073/pnas.1309613110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1309613110</ArticleId><ArticleId IdType="pmc">PMC3704032</ArticleId><ArticleId IdType="pubmed">23781106</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89:1915&#x2013;1922. doi: 10.1212/WNL.0000000000004606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004606</ArticleId><ArticleId IdType="pmc">PMC5664299</ArticleId><ArticleId IdType="pubmed">28978660</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>